01:17 PM EDT, 03/25/2024 (MT Newswires) -- SAB Biotherapeutics ( SABS ) said Monday that the Navy Medical Research Command will conduct a safety study of SAB-176, a potential treatment for influenza type A and B, as part of a research and development agreement between the parties.

Henry Jackson Foundation is funding the pharmacokinetic, safety and tolerability study of SAB-176, according to the company.

SAB Biotherapeutics ( SABS ) shares were down 9.2% in recent trading.

Price: 4.43, Change: -0.45, Percent Change: -9.22